Imbruvica (ibrutinib) — Medica

Initial criteria

• Patient is age ≥ 1 year
• Patient has tried at least one systemic medication for graft-versus-host disease (e.g., corticosteroids, imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, ruxolitinib, belumosudil, axatilimab-csfr, hydroxychloroquine, rituximab, pentostatin, interleukin-2, cyclosporine, tacrolimus, etanercept product)

Reauthorization criteria

• Patient continues to meet initial criteria

Approval duration

1 year